136 related articles for article (PubMed ID: 25827069)
1. Reduced expression and growth inhibitory activity of the aging suppressor klotho in epithelial ovarian cancer.
Lojkin I; Rubinek T; Orsulic S; Schwarzmann O; Karlan BY; Bose S; Wolf I
Cancer Lett; 2015 Jul; 362(2):149-57. PubMed ID: 25827069
[TBL] [Abstract][Full Text] [Related]
2. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
3. Kindlin-2 inhibits serous epithelial ovarian cancer peritoneal dissemination and predicts patient outcomes.
Ren C; Du J; Xi C; Yu Y; Hu A; Zhan J; Guo H; Fang W; Liu C; Zhang H
Biochem Biophys Res Commun; 2014 Mar; 446(1):187-94. PubMed ID: 24583125
[TBL] [Abstract][Full Text] [Related]
4. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression.
Lu L; Katsaros D; Wiley A; de la Longrais IA; Puopolo M; Yu H
Cancer Invest; 2008 Mar; 26(2):185-92. PubMed ID: 18259951
[TBL] [Abstract][Full Text] [Related]
5. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
6. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
[TBL] [Abstract][Full Text] [Related]
7. Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
Seifert H; Georgiou A; Alexander H; McLachlan J; Bodla S; Kaye S; Barton D; Nobbenhuis M; Gore M; Banerjee S
Gynecol Oncol; 2015 Nov; 139(2):216-20. PubMed ID: 26318078
[TBL] [Abstract][Full Text] [Related]
8. BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism.
Wang ZQ; Faddaoui A; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Guillemette C; Gobeil S; Macdonald E; Vanderhyden B; Bachvarov D
Oncotarget; 2015 Oct; 6(31):31522-43. PubMed ID: 26372729
[TBL] [Abstract][Full Text] [Related]
9. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
10. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
Komiyama S; Kurahashi T; Ishikawa M; Tanaka K; Komiyama M; Mikami M; Udagawa Y
Oncol Rep; 2011 Apr; 25(4):1131-8. PubMed ID: 21249319
[TBL] [Abstract][Full Text] [Related]
11. Gene expression analyses support fallopian tube epithelium as the cell of origin of epithelial ovarian cancer.
O'Shannessy DJ; Jackson SM; Twine NC; Hoffman BE; Dezso Z; Agoulnik SI; Somers EB
Int J Mol Sci; 2013 Jul; 14(7):13687-703. PubMed ID: 23880844
[TBL] [Abstract][Full Text] [Related]
12. The expression of asparaginyl endopeptidase promotes growth potential in epithelial ovarian cancer.
Zhu Q; Tang M; Wang X
Cancer Biol Ther; 2017 Apr; 18(4):222-228. PubMed ID: 28278071
[TBL] [Abstract][Full Text] [Related]
13. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
[TBL] [Abstract][Full Text] [Related]
14. Local estrogen metabolism in epithelial ovarian cancer suggests novel targets for therapy.
Ren X; Wu X; Hillier SG; Fegan KS; Critchley HO; Mason JI; Sarvi S; Harlow CR
J Steroid Biochem Mol Biol; 2015 Jun; 150():54-63. PubMed ID: 25817828
[TBL] [Abstract][Full Text] [Related]
15. Cellular distribution of retinoic acid receptor-alpha protein in serous adenocarcinomas of ovarian, tubal, and peritoneal origin: comparison with estrogen receptor status.
Katsetos CD; Stadnicka I; Boyd JC; Ehya H; Zheng S; Soprano CM; Cooper HS; Patchefsky AS; Soprano DR; Soprano KJ
Am J Pathol; 1998 Aug; 153(2):469-80. PubMed ID: 9708807
[TBL] [Abstract][Full Text] [Related]
16. Clinical response to antiestrogen therapy in platinum-resistant ovarian cancer patients and the role of tumor estrogen receptor expression status.
Stasenko M; Plegue M; Sciallis AP; McLean K
Int J Gynecol Cancer; 2015 Feb; 25(2):222-8. PubMed ID: 25500503
[TBL] [Abstract][Full Text] [Related]
17. miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis.
Ge G; Zhang W; Niu L; Yan Y; Ren Y; Zou Y
Oncol Rep; 2016 Mar; 35(3):1816-22. PubMed ID: 26676658
[TBL] [Abstract][Full Text] [Related]
18. Pyridoxine 5'-phosphate oxidase is a novel therapeutic target and regulated by the TGF-β signalling pathway in epithelial ovarian cancer.
Zhang L; Zhou D; Guan W; Ren W; Sun W; Shi J; Lin Q; Zhang J; Qiao T; Ye Y; Wu Y; Zhang Y; Zuo X; Connor KL; Xu G
Cell Death Dis; 2017 Dec; 8(12):3214. PubMed ID: 29238081
[TBL] [Abstract][Full Text] [Related]
19. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.
Kajiyama H; Shibata K; Terauchi M; Ino K; Nawa A; Kikkawa F
Int J Cancer; 2008 Jan; 122(1):91-9. PubMed ID: 17893878
[TBL] [Abstract][Full Text] [Related]
20. SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids.
Ziske MA; Pettee KM; Khaing M; Rubinic K; Eisenmann KM
Biochem Biophys Res Commun; 2016 Mar; 472(1):33-9. PubMed ID: 26898799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
